Expression of indoleamine 2,3-dioxygenase and infiltration of FOXP3+ regulatory T cells are associated with aggressive features of papillary thyroid microcarcinoma

Thyroid

Volumn 24, Issue 8, 2014, Pages 1232-1240

  Ryu, Han Suk ^a   Park, Young Soo ^b   Park, Hyo Jin ^c   Chung, Yul Ri ^a,d   Yom, Cha Kyong ^c   Ahn, Soon Hyun ^c   Park, Young Joo ^d   Park, Seong Hoe ^d   Park, So Yeon ^c,d  

^a Seoul National University Hospital   (South Korea)

^b Asan Medical Center   (South Korea)

^c Seoul National University Bundang Hospital   (South Korea)

^d Seoul National University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

INDOLEAMINE 2,3 DIOXYGENASE; TRANSCRIPTION FACTOR FOXP3; B RAF KINASE; BRAF PROTEIN, HUMAN; CD3 ANTIGEN; FORKHEAD TRANSCRIPTION FACTOR; FOXP3 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER TISSUE; CD3+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL FEATURE; CONTROLLED STUDY; CORRELATIONAL STUDY; DISEASE ASSOCIATION; EXTRATHYROIDAL EXTENSION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; LYMPHOCYTIC INFILTRATION; MAJOR CLINICAL STUDY; MALE; PAPILLARY THYROID MICROCARCINOMA; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROCEDURES; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION; THYROID METASTASIS; THYROID PAPILLARY CARCINOMA; TISSUE SECTION; TUMOR IMMUNITY; TUMOR LOCALIZATION; TUMOR VOLUME; AUTOIMMUNE THYROIDITIS; CELLULAR IMMUNITY; CYTOLOGY; DISEASE COURSE; ENZYMOLOGY; GENETICS; METABOLISM; MIDDLE AGED; MUTATION; PAPILLARY CARCINOMA; THYROID TUMOR; TUMOR ASSOCIATED LEUKOCYTE;

ADULT; AGED; ANTIGENS, CD3; CARCINOMA, PAPILLARY; CD8-POSITIVE T-LYMPHOCYTES; DISEASE PROGRESSION; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; IMMUNITY, CELLULAR; IMMUNOHISTOCHEMISTRY; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; LYMPHATIC METASTASIS; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MIDDLE AGED; MUTATION; PROTO-ONCOGENE PROTEINS B-RAF; T-LYMPHOCYTES, REGULATORY; THYROID NEOPLASMS; THYROIDITIS, AUTOIMMUNE;

EID: 84904707083     PISSN: 10507256     EISSN: 15579077     Source Type: Journal    
DOI: 10.1089/thy.2013.0423     Document Type: Article

References (41)

1. Piersanti M, Ezzat S, Asa SL 2003 Controversies in papillary microcarcinoma of the thyroid. Endocr Pathol 14: 183-191. (Pubitemid 37346700)
2. Mazzaferri EL 2007 Management of low-risk differentiated thyroid cancer. Endocr Pract 13:498-512.
3. Schlumberger MJ 1998 Papillary and follicular thyroid carcinoma. N Engl J Med 338:297-306. (Pubitemid 28065257)
4. Roti E, degli Uberti EC, Bondanelli M, Braverman LE 2008 Thyroid papillary microcarcinoma: a descriptive and meta-analysis study. Eur J Endocrinol 159:659-673.
5. Mercante G, Frasoldati A, Pedroni C, Formisano D, Renna L, Piana S, Gardini G, Valcavi R, Barbieri V 2009 Prognostic factors affecting neck lymph node recurrence and distant metastasis in papillary microcarcinoma of the thyroid: results of a study in 445 patients. Thyroid 19:707-716.
6. Swann JB, Smyth MJ 2007 Immune surveillance of tumors. J Clin Investig 117:1137-1146. (Pubitemid 46718398)
7. Matsubayashi S, Kawai K, Matsumoto Y, Mukuta T, Morita T, Hirai K, Matsuzuka F, Kakudoh K, Kuma K, Tamai H 1995 The correlation between papillary thyroid carcinoma and lymphocytic infiltration in the thyroid gland. J Clin Endocrinol Metab 80:3421-3424. (Pubitemid 3019478)
8. Gupta S, Patel A, Folstad A, Fenton C, Dinauer CA, Tuttle RM, Conran R, Francis GL 2001 Infiltration of differentiated thyroid carcinoma by proliferating lymphocytes is associated with improved disease-free survival for children and young adults. J Clin Endocrinol Metab 86:1346-1354. (Pubitemid 32323027)
9. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C, Tosolini M, Camus M, Berger A, Wind P, Zinzindohoue F, Bruneval P, Cugnenc PH, Trajanoski Z, Fridman WH, Pages F 2006 Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313:1960-1964. (Pubitemid 44498003)
10. Pages F, Kirilovsky A, Mlecnik B, Asslaber M, Tosolini M, Bindea G, Lagorce C, Wind P, Marliot F, Bruneval P, Zatloukal K, Trajanoski Z, Berger A, Fridman WH, Galon J 2009 In situ cytotoxic and memory T cells predict outcome in patients with early-stage colorectal cancer. J Clin Oncol 27:5944-5951.
11. Sato E, Olson SH, Ahn J, Bundy B, Nishikawa H, Qian F, Jungbluth AA, Frosina D, Gnjatic S, Ambrosone C, Kepner J, Odunsi T, Ritter G, Lele S, Chen YT, Ohtani H, Old LJ, Odunsi K 2005 Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+ /regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci U S A 102:18538-18543. (Pubitemid 43011261)
12. Mahmoud SM, Paish EC, Powe DG, Macmillan RD, Grainge MJ, Lee AH, Ellis IO, Green AR 2011 Tumorinfiltrating CD8+ lymphocytes predict clinical outcome in breast cancer. J Clin Oncol 29:1949-1955.
13. Zhu J, Paul WE 2008 CD4 T cells: fates, functions, and faults. Blood 112:1557-1569.
14. Ding ZC, Zhou G 2012 Cytotoxic chemotherapy and CD4+ effector T cells: an emerging alliance for durable antitumor effects. Clin Dev Immunol 2012:890178.
15. Bates GJ, Fox SB, Han C, Leek RD, Garcia JF, Harris AL, Banham AH 2006 Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. J Clin Oncol 24:5373-5380. (Pubitemid 46623168)
16. Petersen RP, Campa MJ, Sperlazza J, Conlon D, Joshi MB, Harpole DH Jr, Patz EF Jr 2006 Tumor infiltrating Foxp3+ regulatory T-cells are associated with recurrence in pathologic stage I NSCLC patients. Cancer 107:2866-2872. (Pubitemid 44937041)
17. Wolf D, Wolf AM, Rumpold H, Fiegl H, Zeimet AG, Muller-Holzner E, Deibl M, Gastl G, Gunsilius E, Marth C 2005 The expression of the regulatory T cell-specific forkhead box transcription factor FoxP3 is associated with poor prognosis in ovarian cancer. Clin Cancer Res 11: 8326-8331. (Pubitemid 41746944)
18. French JD, Weber ZJ, Fretwell DL, Said S, Klopper JP, Haugen BR 2010 Tumor-associated lymphocytes and increased FoxP3+ regulatory T cell frequency correlate with more aggressive papillary thyroid cancer. J Clin Endocrinol Metab 95:2325-2333.
19. Gogali F, Paterakis G, Rassidakis GZ, Kaltsas G, Liakou CI, Gousis P, Neonakis E, Manoussakis MN, Liapi C 2012 Phenotypical analysis of lymphocytes with suppressive and regulatory properties (Tregs) and NK cells in the papillary carcinoma of thyroid. J Clin Endocrinol Metab 97:1474-1482.
20. Della Chiesa M, Carlomagno S, Frumento G, Balsamo M, Cantoni C, Conte R, Moretta L, Moretta A, Vitale M 2006 The tryptophan catabolite L-kynurenine inhibits the surface expression of NKp46- and NKG2D-activating receptors and regulates NK-cell function. Blood 108:4118-4125. (Pubitemid 44913283)
21. Lob S, Konigsrainer A, Rammensee HG, Opelz G, Terness P 2009 Inhibitors of indoleamine-2,3-dioxygenase for cancer therapy: can we see the wood for the trees? Nat Rev Cancer 9:445-452.
22. Munn DH, Shafizadeh E, Attwood JT, Bondarev I, Pashine A, Mellor AL 1999 Inhibition of T cell proliferation by macrophage tryptophan catabolism. J Exp Med 189:1363-1372. (Pubitemid 29227522)
23. Frumento G, Rotondo R, Tonetti M, Damonte G, Benatti U, Ferrara GB 2002 Tryptophan-derived catabolites are responsible for inhibition of T and natural killer cell proliferation induced by indoleamine 2,3-dioxygenase. J Exp Med 196:459-468.
24. Ghossein R 2009 Update to the College of American Pathologists reporting on thyroid carcinomas. Head Neck Pathol 3:86-93.
25. Inaba T, Ino K, Kajiyama H, Shibata K, Yamamoto E, Kondo S, Umezu T, Nawa A, Takikawa O, Kikkawa F 2010 Indoleamine 2,3-dioxygenase expression predicts impaired survival of invasive cervical cancer patients treated with radical hysterectomy. Gynecol Oncol 117: 423-428.
26. Liu X, Shin N, Koblish HK, Yang G, Wang Q, Wang K, Leffet L, Hansbury MJ, Thomas B, Rupar M, Waeltz P, Bowman KJ, Polam P, Sparks RB, Yue EW, Li Y, Wynn R, Fridman JS, Burn TC, Combs AP, Newton RC, Scherle PA 2010 Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity. Blood 115:3520-3530.
27. Uyttenhove C, Pilotte L, Theate I, Stroobant V, Colau D, Parmentier N, Boon T, Van den Eynde BJ 2003 Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat Med 9:1269-1274. (Pubitemid 37279849)
28. Muller AJ, DuHadaway JB, Donover PS, Sutanto-Ward E, Prendergast GC 2005 Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy. Nat Med 11:312-319. (Pubitemid 40460560)
29. Pan K, Wang H, Chen MS, Zhang HK, Weng DS, Zhou J, Huang W, Li JJ, Song HF, Xia JC 2008 Expression and prognosis role of indoleamine 2,3-dioxygenase in hepatocellular carcinoma. J Cancer Res Clin Oncol 134:1247-1253.
30. Ino K, Yamamoto E, Shibata K, Kajiyama H, Yoshida N, Terauchi M, Nawa A, Nagasaka T, Takikawa O, Kikkawa F 2008 Inverse correlation between tumoral indoleamine 2,3- dioxygenase expression and tumor-infiltrating lymphocytes in endometrial cancer: its association with disease progression and survival. Clin Cancer Res 14:2310-2317. (Pubitemid 351551062)
31. Inaba T, Ino K, Kajiyama H, Yamamoto E, Shibata K, Nawa A, Nagasaka T, Akimoto H, Takikawa O, Kikkawa F 2009 Role of the immunosuppressive enzyme indoleamine 2,3-dioxygenase in the progression of ovarian carcinoma. Gynecol Oncol 115:185-192.
32. Urakawa H, Nishida Y, Nakashima H, Shimoyama Y, Nakamura S, Ishiguro N 2009 Prognostic value of indoleamine 2,3-dioxygenase expression in high grade osteosarcoma. Clin Exp Metastasis 26:1005-1012.
33. Liu J, Lu G, Tang F, Liu Y, Cui G 2009 Localization of indoleamine 2,3-dioxygenase in human esophageal squamous cell carcinomas. Virchows Arch 455:441-448.
34. Laimer K, Troester B, Kloss F, Schafer G, Obrist P, Perathoner A, Laimer J, Brandacher G, Rasse M, Margreiter R, Amberger A 2011 Expression and prognostic impact of indoleamine 2,3-dioxygenase in oral squamous cell carcinomas. Oral Oncol 47:352-357.
35. Brandacher G, Perathoner A, Ladurner R, Schneeberger S, Obrist P, Winkler C, Werner ER, Werner-Felmayer G, Weiss HG, Gobel G, Margreiter R, Konigsrainer A, Fuchs D, Amberger A 2006 Prognostic value of indoleamine 2,3- dioxygenase expression in colorectal cancer: effect on tumor- infiltrating T cells. Clin Cancer Res 12:1144-1151. (Pubitemid 43342502)
36. West NR, Kost SE, Martin SD, Milne K, Deleeuw RJ, Nelson BH, Watson PH 2013 Tumour-infiltrating FOXP3(+) lymphocytes are associated with cytotoxic immune responses and good clinical outcome in oestrogen receptornegative breast cancer. Br J Cancer 108:155-162.
37. Yoshioka T, Miyamoto M, Cho Y, Ishikawa K, Tsuchikawa T, Kadoya M, Li L, Mishra R, Ichinokawa K, Shoji Y, Matsumura Y, Shichinohe T, Hirano S, Shinohara T, Itoh T, Kondo S 2008 Infiltrating regulatory T cell numbers is not a factor to predict patient's survival in oesophageal squamous cell carcinoma. Br J Cancer 98:1258-1263. (Pubitemid 351481679)
38. Cunha LL, Morari EC, Nonogaki S, Soares FA, Vassallo J, Ward LS 2012 Foxp3 expression is associated with aggressiveness in differentiated thyroid carcinomas. Clinics 67:483-488.
39. Mansfield AS, Heikkila PS, Vaara AT, von Smitten KA, Vakkila JM, Leidenius MH 2009 Simultaneous Foxp3 and IDO expression is associated with sentinel lymph node metastases in breast cancer. BMC Cancer 9:231.
40. Lee SY, Choi HK, Lee KJ, Jung JY, Hur GY, Jung KH, Kim JH, Shin C, Shim JJ, In KH, Kang KH, Yoo SH 2009 The immune tolerance of cancer is mediated by IDO that is inhibited by COX-2 inhibitors through regulatory T cells. J Immunother 32:22-28.
41. Sznurkowski JJ, Zawrocki A, Emerich J, Sznurkowska K, Biernat W 2011 Expression of indoleamine 2,3-dioxygenase predicts shorter survival in patients with vulvar squamous cell carcinoma (vSCC) not influencing on the recruitment of FOXP3-expressing regulatory T cells in cancer nests. Gynecol Oncol 122:307-312.